Expression of chicken interleukin-2 by turkey herpesvirus increases the immune response against Marek's disease virus but fails to increase protection against virulent challenge.

Abstract

As Marek's disease virus continues to evolve towards greater virulence, more efficacious vaccines will be required in the future. We expressed chicken interleukin-2 (IL-2) from a turkey herpesvirus (HVT) in an attempt to increase the efficacy of HVT as a vaccine against Marek's disease. The recombinant IL-2/HVT was safe for in ovo vaccination, although it replicated less in the birds compared with the parent HVT strain. Expression of IL-2 increased the neutralizing antibody response against HVT but did not increase the protection against virulent Marek's disease virus challenge.

• Authors: I Tarpey, P J Davis, P Sondermeijer, C van Geffen, I Verstegen, V E J C Schijns, Jill Kolodsick, R Sundick
• Journal: Avian pathology : journal of the W.V.P.A (Avian Pathol) Vol. 36 Issue 1 Pg. 69-74 (Feb 2007) ISSN: 0307-9457 [Print] England
• PMID: 17364512 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antibodies, Viral
• Interleukin-2
• Viral Vaccines

Topics

• Animals
• Antibodies, Viral (blood)
• Chick Embryo
• Chickens (genetics)
• Gene Expression
• Herpesvirus 1, Meleagrid (genetics)
• Interleukin-2 (genetics, immunology, metabolism)
• Mardivirus (immunology, pathogenicity)
• Marek Disease (immunology, prevention & control, virology)
• Poultry Diseases (immunology, prevention & control, virology)
• Viral Vaccines (adverse effects, immunology)
• Virulence
• Weight Gain